Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
Payments companies reported to CMS as associated with Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A
These are the largest totals companies reported as associated with Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Alaa Abd-Elsayed | Madison, WI | Pain Medicine | $347,957.23 |
| Matthias Wiederholz | Lawrenceville, NJ | Pain Medicine (Physical Medicine & Rehabilitation) | $158,293.54 |
| Robert Moghim | Golden, CO | Pain Medicine (Anesthesiology) | $151,059.27 |
| Jonathan Silverman | Dayton, OH | Pain Medicine (Physical Medicine & Rehabilitation) | $117,555.33 |
| Jordan Tate | Jasper, GA | Interventional Pain Medicine | $87,961.12 |
| Hesham Elsharkawy | Cleveland, OH | Anesthesiology | $86,703.12 |
| Ryan Pollina | Saint Clair Shores, MI | Interventional Pain Medicine | $65,175.20 |
| Tim Leier | Rancho Mirage, CA | Interventional Pain Medicine | $48,651.39 |
| Earl Kilbride | Austin, TX | Orthopaedic Surgery | $47,854.37 |
| Chad Pletnick | Oro Valley, AZ | Pain Medicine (Anesthesiology) | $43,025.13 |
Prescribed Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.